Search Results

186 Results for "eyenovia".

Sort By

Drug Development

Eyenovia Shares Plummet 70% After It Drops Lead Program

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.

November 15, 2024
·
2 min read
·
Heather McKenzie
Press Releases

Eyenovia Provides Update on Restructuring Efforts

November 22, 2024
·
4 min read
Biotech Bay

NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities

NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.

July 1, 2024
·
8 min read
Press Releases

Eyenovia Provides Update on Phase 3 CHAPERONE Study

November 15, 2024
·
5 min read
Pharm Country

Eyenovia Announces Pricing of $5M Registered Direct Offering

Eyenovia, Inc. providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock.

June 28, 2024
·
5 min read
Press Releases

Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 13, 2024
·
11 min read
Press Releases

Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th

November 8, 2024
·
2 min read
Press Releases

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

October 24, 2024
·
6 min read
Pharm Country

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension

Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.

April 25, 2024
·
10 min read
Press Releases

Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device

October 1, 2024
·
4 min read